Health Care · Pharmaceutical Preparations

ASMB Assembly Biosciences Inc SEC Filings & Insider Trading Activity 2026

company
CIK 142680097 filings

ASMB at a glance

Assembly Biosciences Inc (ASMB, SEC CIK 1426800) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Assembly Biosciences Inc (ASMB) shares worth $226.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by White Nicole S on November 2, 2026 of 29 shares at $20.35 per share.
  • In the last 90 days, ASMB insiders reported 0 open-market purchases ($0) and 8 open-market sales ($238K) on Form 4, a net sale of $238K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$72.3M
+153.5% vs prior year
Insiders · 90 days
0 buys · 8 sells
Net −$238K
13F holders
22 funds
$226.2M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 collaboration revenue $3.0M, down 73% YoY from $10.8M
  • Q3 R&D expenses $20.2M vs $16.6M YoY, driven by 6250 trial startups
  • Best program momentum: 6250 Phase 2 HDV dosing initiated; CLD Phase 2 planned for Q1 2027
  • Operating cash used $54.7M through September, cash and securities $314.3M at September 30
  • Outlook: funds expected to support operations into 2029, including Gilead’s $75.0M extension payment

Risk Factors

  • Newly added regulatory risk: FDA workforce downsizing and eliminated positions could delay inspections, reviews, guidance, and approvals
  • Most materially updated collaboration risk: Gilead declined 4334 licensing in March 2026, potentially slowing development and commercialization
  • Data privacy compliance risk: EU and UK GDPR violations can trigger fines up to €20 million, £17.5 million, or 4% of global revenue
  • Operational risk: Foreign CROs and suppliers face China scrutiny, tariffs, geopolitical disruptions, and supply-chain interruptions
  • Financial risk: Gilead owned approximately 24.4% of common stock and may increase ownership to 35%

AI summary of the ASMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1, relevant for assessing cash runway and clinical funding ability

Item EX-99.1: Item EX-99.1

  • Cash, equivalents and marketable securities $314.3M plus $75M Gilead fee, extending projected runway into 2029
  • 40% U.S. HSV program cost and profit share increases future commercial upside and development spending exposure
Filed Aug 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up from Gilead collaboration estimates
  • Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, helped by collaboration revenue and interest income

Item 2.02: Results of Operations and Financial Condition

  • Assembly Biosciences announced financial results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the substantive financial results and management commentary
Filed Aug 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Assembly Biosciences’ quarter ended June 30, 2026
  • Exhibit 99.1 contains the company’s financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up adjustment tied to Gilead activities
  • Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, supported by higher revenue and interest income

AI summaries of ASMB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ASMB

Don't miss the next ASMB filing

  • Alerts as it files. A push when ASMB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ASMB, by share count.
  • Ask anything. An AI agent that reads every ASMB filing and answers with sources.

ASMB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
White Nicole SSellNov 2, 2026$20.35
Bjorkquist Jeanette MSellNov 2, 2026$20.35
Okazaki Jason ASellNov 2, 2026$20.35
White Nicole SSellNov 2, 2026$19.61
Gaggar AnujSellNov 2, 2026$20.35
Gaggar AnujSellNov 2, 2026$19.61
Bjorkquist Jeanette MSellNov 2, 2026$19.61
Okazaki Jason ASellNov 2, 2026$19.61

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$28.5M$72.3M
Operating Income--$45.4M-$12.1M
Net Income-$61.2M-$40.2M-$6.1M
Op. Margin--159.3%-16.8%
Net Margin--140.9%-8.5%
Balance Sheet
Total Assets$136.8M$119.2M$257.6M
Equity-$33.4M$206.8M
ROE--120.4%-3.0%
Per Share
EPS$-13.38$-6.69$-0.55
Cash Flow
Operating CF--$51.1M-$41.1M
CapEx$255K$28K$66K

Source: XBRL data in Assembly Biosciences Inc (ASMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ASMB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ASMB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$226.2M
Q2 202622$213.8M
Q1 202618$167.7M
Q4 202516$202.4M
Q3 202515$164.1M
Q2 202512$49.7M
Q1 202511$24.9M
Q4 20246$40.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ASMB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
8-KAug 14, 2026Analysis-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026-
4Jun 18, 2026--
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4May 27, 2026-
8-KMay 26, 2026-

Related Health Care companies

All Health Care →

ASMB SEC filings: frequently asked questions

Are ASMB insiders buying or selling?

In the last 90 days, Assembly Biosciences Inc (ASMB) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $237,648 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ASMB stock?

As of September 30, 2026, the largest Assembly Biosciences Inc (ASMB) holders among the 13F filers tracked by SignalX were Gilead Sciences ($116.9 million), BlackRock ($35.0 million), Vanguard Capital Management LLC ($14.2 million), State Street Corp ($13.1 million), Millennium Management ($11.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ASMB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55. The figures come from the XBRL data in the 10-K.

What did ASMB report in its latest 8-K?

Assembly Biosciences Inc (ASMB) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.

What are the latest ASMB SEC filings?

Assembly Biosciences Inc (ASMB) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 3, 2026.

What is ASMB's SEC CIK number?

Assembly Biosciences Inc (ASMB)'s SEC Central Index Key (CIK) is 1426800. EDGAR lists every ASMB filing under that number.

Ask anything about ASMB

The research agent reads ASMB's filings, financials, insider trades and 13F holders, then answers with sources.